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Abstract
Introduction: Acute kidney injury (AKI) following cardiovascular surgery is a common disease process and is
associated with both morbidity and mortality. The aim of our study was to evaluate the cardiovascular and renal
effects of an atrial natriuretic peptide (ANP, carperitide) and a B-type (or brain) natriuretic peptide (BNP, nesiritide)
for preventing and treating AKI in cardiovascular surgery patients.
Methods: Electronic databases, including PubMed, EMBASE and references from identified articles were used for a
literature search.
Results: Data on the infusion of ANP or BNP in cardiovascular surgery patients was collected from fifteen
randomized controlled trials and combined. The infusion of ANP or BNP increased the urine output and creatinine
clearance or glomerular filtration rate, and reduced the use of diuretics and the serum creatinine levels. A meta-
analysis showed that ANP infusion significantly decreased peak serum creatinine levels, incidence of arrhythmia
and renal replacement therapy. The meta-analysis also showed that ANP or BNP infusion significantly decreased
the length of ICU stay and hospital stay compared with controls. However, the combined data were insufficient to
determine how ANP or BNP infusion during the perioperative period influences long-term outcome in
cardiovascular surgery patients.
Conclusions: The infusion of ANP or BNP may preserve postoperative renal function in cardiovascular surgery
patients. A large, multicenter, prospective, randomized controlled trial will have to be performed to assess the
therapeutic potential of ANP or BNP in preventing and treating AKI in the cardiovascular surgical setting.
Keywords: acute kidney injury, atrial natriuretic peptide, B-type (or Brain) natriuretic peptide, cardiovascular surgery,
heart failure, renal function
Introduction
Even with the latest advances in surgical and anesthetic
techniques and postoperative intensive care, patients
undergoing cardiovascular surgery for left ventricular
dysfunction still have a fairly high mortality [1,2]. The
mortality for severe left ventricular dysfunction in
patients undergoing coronary artery bypass grafting is
4.6% to 5.6% and 22.3% to 31% at 30-days and 5 years,
respectively, whereas the mortality for normal left ven-
tricular function is 1.1% to 1.9% and 5.5% to 7% at 30
days and 5 years, respectively[1,2]. These cardiovascular
surgery patients spend prolonged periods in the ICU
and hospital, and their survival is strongly dependent on
their pre-operative left ventricular ejection fraction [1].
Cardiorenal syndrome is another serious concern, as
patients with left ventricular dysfunction also tend to
suffer from acute kidney injury (AKI) [3]. AKI is a com-
mon complication in all patients undergoing cardiovas-
cular surgery. A small percentage (0.7% to 3.4%) of
patients who develop AKI after cardiovascular surgery
require renal replacement therapy, and renal replace-
ment therapy-dependent AKI is an independent risk fac-
tor for early mortality following cardiovascular surgery
[4-6]. To make matters worse, AKI considerably
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surgery [7]. The associated mortality risk is additive in
non-overlapping patients groups; the hazard ratio for
AKI only is 1.41 and for left ventricular dysfunction
only is 1.71. In patients in whom both are present,
hazard ratio is 3.23 [4]. In any case, interventions to
prevent or improve AKI during the perioperative period
are clearly needed for cardiovascular surgery patients.
Atrial natriuretic peptide (ANP), a 28-amino-acid pep-
tide hormone synthesized by the cardiac atria, is a
potent natriuretic, diuretic, and vasorelaxant substance
[8]. ANP increases the pressure within the glomerular
capillaries by dilating afferent renal arterioles and con-
stricting efferent renal arterioles [9], resulting in an
increase in glomerular filtration. ANP has also been
shown to improve renal function in animal models of
acute ischemic renal failure [10,11]. B-type (or brain)
natriuretic peptide (BNP), a 32-amino-acid peptide initi-
ally isolated from porcine brain, was identified as a hor-
mone primarily derived from the cardiac ventricles [12].
The synthesis, secretion and clearance of ANP are dif-
ferent from those of BNP, suggesting discrete pathophy-
siological roles of ANP and BNP in a dual natriuretic
peptide system. ANP is secreted in response to an acute
increase in atrial stretch and/or pressure, while BNP is
regulated at the gene expression level and responds to
increased atrial/ventricular pressure [13,14]. The plasma
half-life of ANP is 3 minutes and that of BNP is 20
minutes.
Two synthetic natriuretic peptides are available for use
as therapeutic agents in patients with acute heart failure:
recombinant human ANP, carperitide (HANP
®, Daiichi-
sankyo Co., Ltd, Tokyo, Japan) and recombinant human
BNP, nesiritide (Natrecor
®, Scios Inc., Sunnyvale, CA,
USA). ANP (carperitide) is commercially available in
Japan and has been used in the treatment of acute heart
failure. BNP (nesiritide) is available in USA, Switzerland,
Argentina, Columbia and Israel [15,16] and has been
used in the treatment of fluid-overloaded patients with
acute heart failure [17,18].
With these points in mind, we reviewed the literature
on the cardiovascular and renal effects of ANP [19] and
BNP in cardiovascular surgery patients in order to gain
insight into potential postoperative treatment for AKI.
Materials and methods
We report our study’s findings in accordance with the
criteria of the PRISMA Group [20]. Electronic databases,
including PubMed, EMBASE and references from identi-
fied articles between January 1994 and January 2011
were used for a literature search relating to the effects
of ANP or BNP on hemodynamics and renal function in
cardiovascular surgery patients. The following key words
were searched: atrial natriuretic peptide or carperitide,
B-type (or brain) natriuretic peptide or nesiritide, acute
kidney injury or acute renal failure, left ventricular dys-
function or heart failure, cardiac surgery or cardiovascu-
lar surgery. The methodological quality of each study
w a sa s s e s s e d .S t u d i e sw e r ee xcluded if they were dupli-
cated studies, reviews, retrospective studies, not cardio-
vascular surgery, not infusion of ANP or BNP, and did
not use a control group. We have evaluated the funding
source of the individual studies.
Statistical analysis
Concerning meta-analysis, we calculated the odds ratio
(OR) and 95% confidence intervals (CI) between the
ANP or BNP group and the control group for need for
hemodialysis, incidence of arrhythmias, and mortality.
We also calculated weighted difference in means and
95% CI between the ANP or BNP group and the control
group for peak serum creatinine levels and length of
ICU stay and hospital stay, by the general variance-
based method.
Results
Of the 893 references screened, 15 randomized con-
trolled trials (RCTs) of the infusion of ANP or BNP in
cardiovascular surgery patients were included in sys-
tematic review and 9 studies for meta-analysis (Figure
1). Most of the studies described single-center studies
with small samples sizes. Tables 1 and 2 show the
respective effects of ANP and BNP on hemodynamics,
renal function, and other parameters in cardiovascular
surgery patients. The methodological quality of the
included studies was as follows. The patients were ran-
domly allocated in all studies. Allocation concealment
was adequate in 11 studies [21-31], which blinded the
participants and the investigators, and unclear in the
remaining studies. Four studies [[25,27] to [29]]
excluded withdrawals after randomization, but the
remaining eleven studies did not have withdrawals.
Completeness of follow up was adequate in all studies.
There was no relationship between funding source and
ANP or BNP in these studies. The main results of the
meta-analysis were as follows: ANP infusion significantly
decreased peak serum creatinine levels, incidence of
arrhythmia and need for renal replacement therapy (Fig-
ure 2), and ANP or BNP infusion significantly decreased
the length of ICU stay and hospital stay compared with
controls, but not mortality compared with controls (Fig-
ures 3 and 4).
ANP studies
ANP infusion decreased the mean pulmonary arterial
pressure [32,33], pulmonary capillary wedge pressure
[32,34], central venous pressure or right atrial pressure
[21,32,34], systemic vascular resistance index [21,34], and
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change the heart rate or mean arterial pressure [22,33].
There is some disagreement in the reported effects of
ANP on cardiac index. Bergman et al.[ 2 2 ]s h o w e da
decrease in cardiac index after ANP infusion, whereas
Hayashi et al.[ 3 2 ]a n dH a y a s h i d aet al.[ 3 4 ]s h o w e da n
increase in cardiac index. A meta-analysis showed that
ANP infusion significantly decreased the incidence of
arrhythmias compared with controls [23,27] (Figure 2).
ANP infusion increased urine output [21,22,24,34,35],
increased creatinine clearance or glomerular filtration
rate (GFR) [21,22,25-27,35], decreased serum creatinine
levels [24,26,27,35], and decreased the furosemide dosage
[21,24,32], compared with controls. ANP infusion also
decreased the incidence of renal replacement therapy
compared with controls [25,26]. The meta-analysis
showed that ANP infusion significantly decreased peak
serum creatinine levels and the need for renal replace-
ment therapy compared with controls (Figure 2). ANP
infusion increased plasma cyclic guanosine 3’,5’-mono-
phosphate (cGMP) levels [21,34] but decreased plasma
BNP levels [23,24,27], compared with controls. ANP
infusion decreased renin and aldosterone [21,32] and
pleural effusion [21] compared with controls. ANP infu-
sion increased renal replacement therapy-free survival at
21 days compared with controls [25]. The meta-analysis
showed that ANP infusion significantly reduced the
length of ICU stay and hospital stay, but not mortality
compared with controls (Figure 3).
BNP studies
BNP infusion did not change the pulmonary arterial
pressure [28]. Over the first 24 hours after surgery, BNP
infusion significantly attenuated the peak increase in
serum creatinine, significantly attenuated the fall in
GFR, and increased urine output, compared with con-
trols [28]. BNP infusion decreased plasma cystatin levels
and maintained creatinine clearance, compared with
controls [29]. BNP infusion decreased the incidence of
AKI, decreased serum creatinine levels, and increased
GFR, compared with controls, but there were no differ-
ences between the BNP and control groups in mortality
or the incidence of renal replacement therapy [30]. In
one study, the urine output and furosemide dosage were
not significantly different between the BNP and control
groups [31]. BNP infusion increased plasma cGMP
Figure 1 Flow diagram of study selection. ANP, atrial natriuretic peptide; BNP, B-type (or brain) natriuretic peptide.
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Page 3 of 10Table 1 Effects of ANP on hemodynamics, renal function, and other parameters in patients undergoing cardiovascular
surgery
Author, year,
journal,
country
and study
type
Patient group Surgical procedure and dose of ANP Effects of ANP on hemodynamics, renal function,
and other parameters
ANP
(n)
Control
(n)
Bergman A, et
al. [22], 1996
J Cardiothorac
Vasc Anesth,
Sweden, RCT
15 15 Elective CABG on CPB, normal renal function
ANP 7.5 pMol/kg/min, after operation for 3 hrs,
MAP®,H R ®, PCWP®, RAP®,C I ↓
Urine output↑, inulin clearance↑,F F ↑, FENa↑
Hayashida N, et
al. [34], 2000
Ann
ThoracSurg,
Japan, RCT
9 9 Elective mitral valve surgery on CPB
ANP 0.05 μg/kg/min, after initiation of CPB for 6 hrs
PCWP↓, RAP↓, SVR↓,C I ↑,
Urine output↑, FENa↑, plasma cGMP↑, plasma BNP↓,
Sezai A, et al.
[21], 2000
Ann Thorac
Surg, Japan,
RCT
20 20 Elective CABG on CPB.
ANP (SBP > 120 mmHg,0.05 μg/kg/min; SBP ≤ 120
mmHg,
0.03 μg/kg/min), after initiation of CPB for 24 hrs
®0.02 μg/kg/min for 4 hrs,
CVP↓, SVRI↓, PVRI↓, plasma cGMP↑,
Urine output↑, GFR↑, renin↓, angiotensin II↓,
aldosterone↓, pleural effusion↓, furosemide↓
Hayashi Y, et al.
[32], 2003
ASAIO Journal,
Japan, RCT
14 16 Selective open heart operation on CPB
ANP 0.025 μg/kg/min, after CPB for 72 hrs,
CVP↓, MPAP↓, PCWP↓,C I ↑,
furosemide↓, KCL↓, renin↓, aldosterone↓
Swärd K, et al.
[25], 2004
Crit Care Med,
Sweden
RCT
29 30 Cardiac surgery, preoperative normal renal function,
SCr > 50%↑, ANP 50 ng/kg/min®SCr decreased below
the trigger value or RRT
Ccr↑, incidence of renal RRT on day 21 (ANP group
21% versus Control group 47%)↓
RRT-free survival at day 21↑
Sezai A, et al.
[23], 2007
Circ J, Japan,
RCT
63 61 Emergent CABG on CPB
ANP 0.02 μg/kg/min at the start of CPB®0.01 μg/kg/min
for 12 hrs
Peak CK-MB↓, arrhythmias↓, plasma BNP↓,
furosemide↓, KCL↓
Izumi K, et al.
[35], 2008
Ann Thorac
Cardiovasc
Surg,
Japan, RCT
10 8 Elective cardiac surgery on CPB, SCr ≥ 1.2 mg/dl
ANP 0.02 μg/kg/min, for 5 days or more
Urine output↑, SCr↓, Ccr↑, urinary NAG↓
Mitaka C, et al.
[24], 2008
Crit Care Med,
Japan
RCT
20 20 Elective abdominal aortic aneurysm repair, SCr < 3 mg/dl
ANP 0.01-0.05 μg/kg/min, before aortic cross clamping
®for 48 hrs
Urine output↑, SCr↓, Ccr↑, BUN↓, urinary NAG/Cr↓,
plasma ANP ↑, plasma BNP ↓,
furosemide↓
Sumi K, et al.
[33], 2008
J Cardiothorac
Vas Anesth,
Japan, RCT
30 15 Infrarenal abdominal aortic aneurysmectomy
ANP 0.02 and 0.05 μg/kg/min, respectively,
5 min after aortic clamping®end of operation
MAP®, MPAP↓, PVRI↓, SVRI®
Sezai A, et al.
[26], 2009
J Am Coll
Cardiol, Japan
RCT
251 253 Elective CABG on CPB, SCr < 1.3 mg/dl, Ccr ≥ 80 ml/min,
ANP 0.02 μg/kg/min, at the start of CPB®0.01 μg/kg/min
for 12 hrs
SCr↓, Ccr↑, SCr > 2.0 mg/dl (ANP group; n =1 ,
Control group; n = 8), RRT (ANP group; n =0 ,
Control group;n =4 )
Sezai A, et al.
[27], 2010
J Am Coll
Cardiol, Japan
RCT
68 65 Cardiac surgery on CPB, LVEF ≤ 35%,
ANP 0.02 μg/kg/min, at the start of CPB®0.01 μg/kg/min
for 12 hrs
LVEF↑, eGFR↑, SCr↓, plasma BNP↓, arrhythmias↓,
mortality (NS), cardiac death-free rate at 5 or 8 years
(ANP group; 98.5%, control group; 85.5%)
AKI, acute kidney injury; ANP, atrial natriuretic peptide; BNP, B-type (or brain) natriuretic peptide; BUN, blood urea nitrogen; CABG, coronary artery bypass graft;
cGMP, cyclic guanosine, 3’,5’-monophosphate; CI, cardiac index; CPB, cardiopulmonary bypass; CVP, central venous pressure; Ccr, creatinine clearance; eGFR,
estimated glomerular filtration rate; FF, filtration fractional; FENa, fractional sodium excretion; GFR, glomerular filtration rate; HR, heart rate; LVEF, left ventricular
ejection fraction; MAP, mean arterial pressure; MPAP, mean pulmonary arterial pressure; NAG, N-acetyl-beta-D-glucosaminidase; n, number; NS, not significant;
PCWP, pulmonary capillary wedge pressure; PVRI, pulmonary vascular resistance index; RAP, right atrial pressure; RCT, randomized controlled trial; RRT, renal
replacement therapy; SCr, serum creatinine; SVR: systemic vascular resistance, SVRI: systemic vascular resistance index.
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Page 4 of 10levels [29] and decreased plasma ANP levels [31] com-
pared with controls. Time to extubation and PaO2/FIO2
ratio at 48 hours were not significantly different between
the BNP group and the control group [31]. One study
showed a shorter ICU stay and reduced 180-day mortal-
ity in the BNP group compared with the control group
[28]. The meta-analysis showed that BNP infusion signifi-
cantly reduced the length of ICU stay and hospital stay,
but not mortality compared with controls (Figure 4).
Discussion
AKI after cardiac surgery is associated with an increased
risk of morbidity, mortality, and length of ICU and hos-
pital stay [4-6]. In a retrospective study of 2,973
patients, long-term mortality after cardiothoracic surgery
was proportional to severity of AKI, as defined by RIFLE
(Risk, Injury, Failure, Loss, and End stage) classification
[36]. In addition, duration of AKI is associated with
long-term mortality after cardiac surgery [37]. There-
fore, severity and duration of AKI have important impli-
cations for patient care. The predominant causes of AKI
in patients undergoing cardiovascular surgery are hypo-
perfusion and inflammation because of cardiopulmonary
bypass (CPB). The nonpulsatile flow during CPB has
been shown to cause AKI by inducing vasoconstriction
and ischemic renal injury [38]. There appear to be other
mechanisms responsible for AKI, however, as even
patients who undergo surgery off CPB (off-pump) are at
risk for AKI. The pathophysiology of AKI is multifactor-
ial. Cardiac-surgery-associated AKI is caused by exogen-
ous and endogenous toxins, metabolic factors, ischemia
and reperfusion, neurohormonal activation, inflamma-
tion, and oxidative stress [39]. Similar to cardiac surgery,
AKI is the most common complication in patients
undergoing pararenal aortic aneurysm repair. Suprarenal
aortic cross-clamping is associated with a significant
postoperative decline in renal function [40]. Even infra-
renal aortic cross-clamping is associated with an
increase in renal vascular resistance and a decrease in
renal blood flow [41]. Therefore, in addition to cardiac
surgery, we have included abdominal aortic aneurysm
repair as one of cardiovascular surgery. The risk of AKI
can therefore be reduced by maintaining adequate
hemodynamics and an adequate metabolic state, avoid-
ing nephrotoxic drugs, and inhibiting neurohormonal
activation and inflammation during perioperative
periods.
Furosemide is frequently used to facilitate fluid and
electrolyte management of AKI. However, meta-analysis
has shown that furosemide is not associated with any
Table 2 Effects of BNP on hemodynamics, renal function, and other parameters in patients undergoing cardiovascular
surgery
Author, year,
journal,
country
and study
type
Patient
group
Surgical procedure and dose of BNP Effects of BNP on hemodynamics, renal function, and other
parameters
BNP
(n)
Control
(n)
Mentzer RM, et
al. [28], 2007
J Am Coll
Cardiol, USA,
RCT
137 135 CABG on CPB, LVEF ≦ 40%,
BNP 0.01 μg/kg/min,
after anesthesia for 24-96 hrs
PAP (NS), urine output during the initial 24 hrs (BNP group, 2926 ±
1179 ml vs. Control group 2350 ± 1066 ml, P < 0.001), peak increase
in SCr (BNP group, 0.15 vs. Control group, 0.34, P < 0.001), max
decrease in GFR (BNP group, -10.8 ml/min/1.73 m
2 vs. Control group,
-17.2 ml/min/1.73 m
2, P= 0.001), length of hospital stay↓, 180-day
mortality↓
Chen HH, et al.
[29], 2007
Circulation,
USA
RCT
20 20 Cardiac surgery on CPB, Ccr < 60 ml/min,
BNP 0.005 μg/kg/min, after anesthesia for
24 hrs
Ccr↑, plasma cystatin↓, plasma BNP↑, plasma cGMP↑, aldosterone↓
Beaver TM, et
al. [31], 2008
J Card Surg,
USA
RCT
9 10 Maze and mitral valve surgery, BNP 0.01
μg/kg/min, 3 hrs after CPB for 72 hrs
Urine output (NS), plasma ANP↓, furosemide doses (NS), time to
extubation (NS), PaO2/FIO2 at 48 hrs (NS)
Ejaz AA, et al.
[30], 2009
J Thorac
Cardiovasc
Surg, USA
RCT
45 49 High-risk cardiac surgery, BNP 0.01 μg/kg/
min, before surgery®for 5 days
SCr ↓, GFR↑, incidence of AKI ↓, incidence of RRT (NS), all cause of
mortality through day 21 (NS), length of hospital stay (NS)
AKI, acute kidney injury; ANP, atrial natriuretic peptide; BNP, B-type (or brain) natriuretic peptide; CABG, coronary artery bypass graft; Ccr, creatinine clearance;
cGMP, cyclic guanosine 3’,5’-monophsphate; CPB, cardiopulmonary bypass; GFR, glomerular filtration rate; LVEF, left ventricular ejection fraction; n, number; NS,
not significant; PAP, pulmonary arterial pressure; RCT, randomized controlled trial; RRT, renal replacement therapy; SCr, serum creatinine
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Page 5 of 10significant clinical benefits in the prevention and treat-
ment of AKI and high doses may even be detrimental
[42].
The cardiovascular effects of ANP or BNP are vaso-
dilation and a reduced sympathetic tone in the periph-
eral vasculature [9]. ANP and BNP bind to natriuretic
peptide receptor A, which increases cGMP and dilates
veins and arteries [9], and thereby reduces preload and
afterload. ANP, meanwhile, decreases pulmonary capil-
lary wedge pressure, central venous pressure, mean
pulmonary arterial pressure, pulmonary vascular resis-
tance index, and systemic vascular resistance index
[21,32-34]. The ANP patient group also had a reduced
incidence of arrhythmias compared with controls
[23,27]. The reduction of arrhythmia may be attributa-
ble to stable serum potassium levels, as the dose of
furosemide and rate of KCl correction are lower in the
ANP groups than in the controls [23,32]. However,
arrhythmias may be caused by many different factors,
including hypomagnesemia, myocardial injury from
surgical handling, inflammation after cardiac surgery,
acute atrial enlargement from volume overload, inade-
quate cardioprotection during CPB, and hyperadrener-
gic state. Although the true mechanism is unknown,
we surmise that the anti-arrhythmic effects of ANP are
d u et op r e v e n t i o no fv o l u m eo v e r l o a da n ds u p p r e s s i o n
of the sympathetic nervous system except for potas-
sium levels.
The natriuretic and diuretic actions of ANP and BNP
are caused by renal hemodynamic and direct tubular
actions [9]. ANP increases transcapillary filtration pres-
sure within the glomerulus [10], and this then translates
to an increase in GFR. The protective effect of ANP for
the kidney may take place via the ANP-induced
increases in the medullary vasa recta blood flow [43], an
action that may protect against medullary ischemia. In
one study, the urinary N-acetyl-b-D-glucosaminidase
(NAG)/creatinine ratio, an index of renal tubular
damage, was significantly lower in the ANP group than
in the control group [24].
Figure 2 Effect of atrial natriuretic peptide (ANP) infusion on arrhythmias, peak serum creatinine (sCr) levels and need for renal
replacement therapy. Size of data markers is proportional to the weight of each study in the forest plot. N, number of patients; Horizontal bars
= 95% confidence interval (CI).
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Page 6 of 10ANP or BNP infusion increased urine volume, creati-
nine clearance and GFR and decreased serum creatinine
in patients with normal renal function [22,26]. ANP or
BNP infusion also attenuated serum creatinine increase
and maintained creatinine clearance and GFR in patients
with preoperative renal dysfunction [35], in patients with
AKI after cardiac surgery [25] and in patients with left
ventricular ejection fraction (LVE F) ≤40% [28]. Espe-
cially, Mentzer et al. [28] have shown that the beneficial
effects of BNP on postoperative renal dysfunction were
prominent in patients with renal dysfunction at baseline
serum creatinine (Cr) > 1.2 mg/dl. In these patients, BNP
significantly inhibited serum creatinine increase and GFR
decrease compared with those of normal renal function.
Therefore, the renal effects of ANP and BNP may depend
on degree of underlying renal function.
Although 10 of 15 studies did not mentioned fluid
balance, some of the studies suggest that the control
groups were given more volume. This may be relevant
to recent studies on AKI and volume loading [44],
which have shown that adequate volume repletion is of
major importance for prevention of AKI.
ANP and BNP also suppress the renin-angiotensin-
aldosterone axis [9], thereby counterbalancing the
vasoconstrictive effects of these neurohormones. In fact,
two clinical studies have shown that ANP infusion
decreases renin and aldosterone compared with controls
[21,32]. The effects of ANP in preserving the peritubular
capillary blood flow and suppressing the renin-angioten-
sin system may protect against renal tubular damage
after cardiovascular surgery. The cardiovascular and
renal effects of ANP and BNP and the action of these
natriuretic peptides in manipulating the renin-angioten-
sin-aldosterone axis may help to prevent serious AKI in
the management of patients with cardio-renal syndrome.
The major site of ANP synthesis is the atrium, and
ANP mRNA levels are considerably higher in the atrium
than in the ventricles. However, ventricular ANP expres-
sion is re-induced in heart failure. Although concentra-
tions of BNP and BNP mRNA are much lower in the
ventricle than in the atrium, the total content of BNP
and BNP mRNA in the ventricle accounts for 30% and
70% of that in the whole heart, respectively. In patients
with congestive heart failure, concentrations of myocar-
dial BNP mRNA and circulating BNP are increased
more than are those of ANP, suggesting that BNP plays
t h er o l eo fa ne m e r g e n c yh o r m o n ea g a i n s tv e n t r i c u l a r
overload. The characteristic feature of BNP mRNA that
Figure 3 Effect of atrial natriuretic peptide (ANP) infusion on length of ICU stay and hospital stay and mortality. Size of data markers is
proportional to the weight of each study in the forest plot. N, number of patients; Horizontal bars = 95% confidence interval (CI).
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Page 7 of 10is different from ANP mRNA is a conserved sequence
consisting of repeated AUUUA units in the 3’ untrans-
lated region. The presence of this sequence accelerates
the degradation of BNP mRNA. Therefore, BNP gene
expression is regulated differently from ANP gene
expression and is thought to dynamically change,
depending on the physiological and pathophysiological
conditions [45]. While ANP and BNP seem to play dis-
crete pathophysiological roles in a dual natriuretic pep-
tide system [14,15], their roles may also be
compensatory in relation to each other. ANP and BNP
bind to the same natriuretic peptide receptor A [9] and
this may lead to mutual biological invasion of ANP and
BNP. ANP infusion decreases plasma BNP levels in
patients undergoing cardiovascular surgery, while BNP
infusion decreases plasma ANP levels in the same
patients [23,24,31,34]. This tells us that ANP and BNP
are closely related.
There are many natriuretic peptide receptors A in the
body. If there are some unoccupied natriuretic receptors
A on the various target cells, exogenous ANP (or BNP)
may bind to these receptors, leading to biological effects.
In fact, in patients with high plasma BNP levels (> 230
pg/ml), the effect of ANP infu s i o no nl e f tv e n t r i c u l a r
contractility was blunted but its beneficial effects on left
ventricular diastolic function and left ventricular-arterial
coupling remained [46]. Thus, ANP infusion may
improve left ventricular diastolic function even in
patients with high plasma levels. Taken together, extra
ANP (or BNP) are likely to confer benefit, even if the
endogenous system is at full capacity.
Limitations of this meta-analysis
First, few studies use the same protocols and the end
points are vastly different. The primary endpoints in
most of the studies were continuous changes in serum
creatinine and creatinine clearance or GFR. The clini-
cally important endpoints of renal replacement therapy
and/or mortality were considered primary outcomes in
only seven of the studies [23,25-30], and most of the
studies lacked the robustness to demonstrate beneficial
effects of ANP or BNP on mortality. Second, the
included studies had patients with different renal func-
tions and differed significantly in doses, timing of initia-
tion and duration of ANP or BNP treatments. These
facts restrict comparing these studies with each other
Figure 4 Effect of B-type (or brain) natriuretic peptide (BNP) infusion on length of ICU stay and hospital stay and mortality.S i z eo f
data markers is proportional to the weight of each study in the forest plot. N, number of patients; Horizontal bars = 95% confidence interval (CI).
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were no standard indications for renal replacement ther-
apy, the decision to initiate renal replacement therapy
was dependent on the participating doctors. Therefore,
there may be a wide variation in the incidence of renal
replacement therapy. Fourth, four out of eleven studies
were performed by the same group of investigators in
the same institution. Accordingly, the results may be
biased more slightly toward the studies of this group.
Finally, as a marker of renal function there are some
shortcomings of creatinine because serum creatinine is
affected by age, gender, muscle mass, nutritional status
and analytical interference, although AKI has been
defined largely by changes in creatinine. Estimated GFR
formulae based on serum creatinine, age, sex and weight
are used in daily clinical practice, but their accuracy is
debatable. In addition, a 24 hour urine creatinine clear-
ance has been commonly employed for the detection of
AKI. However, since a substantial fraction of urinary
creatinine is derived from tubular secretion, creatinine
clearance regularly overestimates GFR [47]. Accordingly,
we have to interpret the results carefully by considering
the shortcomings of creatinine.
Even so, ANP and BNP have cardiovascular and renal
effects as well as effects in manipulating the renin-
angiotensin-aldosterone axis. On these grounds, we
speculate that ANP and BNP may be able to prevent or
treat for AKI in cardiovascular surgery patients. The
infusion of ANP or BNP in these patients should be
investigated more thoroughly.
Conclusions
The infusion of ANP or BNP may preserve renal func-
tion after cardiovascular surgery. Only seven studies
have researched the incidence of renal replacement ther-
apy and the longer-term outcome in patients after cardi-
ovascular surgery. The meta-analysis showed that ANP
infusion significantly decreased peak serum creatinine
levels, incidence of arrhythmia and renal replacement
therapy, and ANP or BNP infusion significantly
decreased the length of ICU stay and hospital stay com-
pared with controls. A large, muticenter, prospective,
randomized controlled trial will have to be performed to
assess the therapeutic potential of ANP or BNP in pre-
venting and treating AKI in the cardiovascular surgical
setting.
Key messages
￿ Data on infusion of ANP and BNP in cardiovascu-
lar surgery patients was collected from fifteen RCTs
and combined.
￿ ANP infusion increased urine output and the crea-
tinine clearance or GFR, and reduced the use of
diuretics and the serum creatinine levels compared
with controls.
￿The meta-analysis showed that ANP infusion signif-
icantly decreased peak serum creatinine levels, the
incidence of arrhythmia and hemodialysis, and ANP
or BNP infusion significantly decreased the length of
ICU stay and hospital stay compared with controls.
￿ The combined data were insufficient to determine
how ANP or BNP infusion during the perioperative
period affect the long-term outcome in cardiovascu-
lar surgery patients.
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